한빛사논문
- 조회656
Min Young Kim 1, Hyun Young Shin 2 3, Sung Chun Cho 4, Sohae Yang 1, Aseer Intisar 1, Hyeong Jung Woo 1, Youn-Suk Choi 5, Chang-Lim You 6, Jong-Sun Kang 6, Yun-Il Lee 4, Sang Chul Park 7, Kyungmoo Yea 1, Tae Gyu Oh 8, Michael Downes 8, Ronald M Evans 8, Minseok S Kim 1 2 9 10 *
1Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Republic of Korea.
2CTCELLS, Inc., Daegu 42988, Republic of Korea.
3SBCure Corp., Daegu 43017, Republic of Korea.
4Well Aging Research Center, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Republic of Korea.
5Samsung Advanced Institute of Technology, Samsung Electronics Co. Ltd., Suwon 16678, Republic of Korea.
6Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea.
7Chonnam National University Medical School, Gwangju 61186, Republic of Korea.
8Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037.
9Translational Responsive Medicine Center, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Republic of Korea.
10New Biology Research Center, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Republic of Korea.
*Corresponding author: correspondence to Minseok S Kim
Abstract
While the world is rapidly transforming into a superaging society, pharmaceutical approaches to treat sarcopenia have hitherto not been successful due to their insufficient efficacy and failure to specifically target skeletal muscle cells (skMCs). Although electrical stimulation (ES) is emerging as an alternative intervention, its efficacy toward treating sarcopenia remains unexplored. In this study, we demonstrate a silver electroceutical technology with the potential to treat sarcopenia. First, we developed a high-throughput ES screening platform that can simultaneously stimulate 15 independent conditions, while utilizing only a small number of human-derived primary aged/young skMCs (hAskMC/hYskMC). The in vitro screening showed that specific ES conditions induced hypertrophy and rejuvenation in hAskMCs, and the optimal ES frequency in hAskMCs was different from that in hYskMCs. When applied to aged mice in vivo, specific ES conditions improved the prevalence and thickness of Type IIA fibers, along with biomechanical attributes, toward a younger skMC phenotype. This study is expected to pave the way toward an electroceutical treatment for sarcopenia with minimal side effects and help realize personalized bioelectronic medicine.
논문정보
- Research article
- 2023년 08월 (BRIC 등록일 2023-08-14)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
